-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VD5ZSpGFCZ1GYIpDROo+/DczMPkSClAKOHF3NmBSVr7QlufbJBptNFwpBW0BBgE0 jsZJTfgGy2owOvMtxIPO/Q== 0000947871-10-000969.txt : 20101004 0000947871-10-000969.hdr.sgml : 20101004 20101004132323 ACCESSION NUMBER: 0000947871-10-000969 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20101004 DATE AS OF CHANGE: 20101004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH, PIERCE, FENNER & SMITH INC. CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-92161 FILM NUMBER: 101104863 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2126702273 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 FORMER COMPANY: FORMER CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC DATE OF NAME CHANGE: 19920929 424B3 1 ss102006_424b3-pharm.htm PROSPECTUS SUPPLEMENT

PROSPECTUS SUPPLEMENT
REGISTRATION NO.  333-92161
(To Prospectus dated April 15, 2010)
Filed Pursuant to Rule 424(b)(3)
 

 

 
1,000,000,000 Depositary Receipts
Pharmaceutical HOLDRS (SM) Trust
 
This prospectus supplement supplements information contained in the prospectus dated April 15, 2010 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS Trust.
 
The share amounts specified in the table in the “Highlights of Pharmaceutical HOLDRS” section of the base prospectus shall be replaced with the following:
 
Name of Company1
  
Ticker
  
Share
Amounts
    
Primary
Trading
Market
Abbott Laboratories
  
ABT
   14.0000    
NYSE
Allergan, Inc.
  
AGN
   2.0000    
NYSE
Bristol-Myers Squibb Company
  
BMY
   18.0000    
NYSE
Eli Lilly & Company
  
LLY
   10.0000    
NYSE
Forest Laboratories, Inc.
  
FRX
   4.0000    
NYSE
Hospira, Inc.
  
HSP
   1.4000    
NYSE
Johnson & Johnson
  
JNJ
   26.0000    
NYSE
King Pharmaceuticals, Inc.
  
KG
   4.2500    
NYSE
Medco Health Solutions, Inc.
  
MHS
   5.3064    
NYSE
Merck & Co., Inc.
  
MRK
   30.0738    
NYSE
Mylan Laboratories, Inc.
  
MYL
   2.2500    
NASDAQ GS
Pfizer Inc.
  
PFE
   69.8200    
NYSE
Valeant Pharmaceuticals International, Inc.
  
VRX
   5.7809    
NYSE
Watson Pharmaceuticals, Inc.
  
WPI
   1.0000    
NYSE
Zimmer Holdings Inc.
  
ZMH
   1.8000    
NYSE

The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

The date of this prospectus supplement is October 4, 2010.
 

1 On September 28, 2010, the merger of Valeant Pharmaceuticals International and Biovail Corporation became effective.  Also, effective September 28, 2010, Biovail Corporation changed its name to (New) Valeant Pharmaceuticals International, Inc.  As a result, (Old) Valeant Pharmaceuticals International, Inc. will no longer be an underlying constituent of the Pharmaceutical HOLDRS Trust.  In connection with the merger, (Old) Valeant Pharmaceuticals International, Inc. shareholders will receive 1.7809 shares of (New) Valeant Pharmaceuticals International, Inc.  The Bank of New York Mellon will receive 1.7809 shares of (New) Valeant Pharmaceuticals International, Inc. per 100 sh are round lot of Pharmaceutical HOLDRS.  As a result, once the allocation has been completed by The Depository Trust Company, creations of Pharmaceutical HOLDRS will require a deposit of 5.7809 shares of (New) Valeant Pharmaceuticals International, Inc. per 100 share round lot of Pharmaceutical HOLDRS.
 
 
 
GRAPHIC 2 pharm.jpg GRAPHIC begin 644 pharm.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``("`@("`@("`@("`@("`@,"`@(" M`P,#`P,#`P,$`P,#`P,#!`0$!`4$!`0%!08&!04'!P<'!P<'!P<'!P<'!P?_ MVP!#`0("`@,#`P4$!`4'!@4&!P@("`@("`@'!P<'!P<'!P<'!P<'!P<'!P<' M!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P?_P``1"`!:`4(#`1$``A$!`Q$!_\0` M'0`!``("`P$!``````````````<(!08!!`D"`__$`%,0```%`P(#`P0*#0D' M!0````$"`P0%``81!Q(3%"$(%3$6(D%A%Q@C,C=15F5Q\"0E*#,T-39"57:! MI;548F21E)6AL=4F0T5'5Z;48Z/!T_'_Q``<`0$``@,!`0$````````````` M!@<$!0@#`@G_Q`!3$0`!`P(#!0($#PT%"`,````!``(#!!$%$B$&!Q,B,4%A M%#)1\`@5%A<8(S,V0E)35&)TLS5C97&!@Y&2H:.DT^0E)S2TU$."DZ*QLM+A M)%64_]H`#`,!``(1`Q$`/P#W\HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2 MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41 M*(E$2B)1$HB41*(E$2B)1%P(@'B(!U`.OQB.`#]HT1<%,4_4IBF#XRCGQ#(> M'J'-$0#%';@Q1W%W%P/B'3J'JZA1%]41*(E$2B)1$HB41*(E$2B)1$HB41*( ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBB6;UEM>/ESV[ M;S"Y-1KB;23:,EX?3MB65[G4=+.6Q!FY(ZK>+C=B[51-0CIV10GOS$!,#'+O M*?`*A\7%E_1P(+6D'H#?1:.HQ^G9+PHFOGD!`92R^SJ`">%BR\`B MX?RL@*I_[])4,>W]BP?+5#@_Z,$;F#_BR:_[ARGX)&OC_;4_R-.TL^E/(UY_ MX4>G^^+CX0.FD/+/[2\:0CV(UYB;F>M7399*#G[*AXV-?$!P45F[M[%BX>)$ M,ET$6Y-PY`"J)[BJUG,Q3`'G*_#W,:0>9DSGN;IH0UUFDW\IMW'H<%^%X^P9 MF8@U[@1ROA:UKM=07-NX"WD%^\=1T=&^T=-75>$KIAJ;:C:S]0(E!=P8K1P! M&C\R!MYT&C5XNHH4Y6ADUT^"NX(X2!5P4R9"E`_KM!LM#2TC*ZCE,M,\CLU; M?M)``MF!:;AA:[*RQ-UY;/[4S556^BK(A%4L![='6[`"2;Y2'"Q>'-S/N!96 MS34(?.!ZFP;:)BF_,*/3:8>G4/\`/TY&%*:K]J(E$2B)1$HB41*(E$2B)1$H MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%`.JFN7L9W`S@O)COKFH9*7 MYKO(&>WBN'*'"X?*KYQR^=V[T^'3-4EO)WQ>I/$XZ+P'PC/"V7-Q>';,^1F6 MW!D^)>]^VUO+8^R&[_T\HWU'A/"RR%ELF?HUKKWXC/C6M;LZ^2?JNU5PE$4` MZJ:Y>QG<#."\F.^N:ADI?FN\@9[>*X*H5%/BN'! MB)DWJ'*0NXW4P@`=1KU@IY9GAD;2]QZ!H))[>@UZ+RGJ(H6%\C@QHZEQ``[. MITZKLO&J3]FZ8KF-E6JQV;APT<%(J04S"@[:'2<('`!\U1(Y3D'SBF`P M`-?,;RQP<+7!OJ`1^4&X([B"#VKZD8'M+3>Q%M"0?R$6(/>"".Q8VW+<@[1@ MXVVK:C6T1!Q#8&L?'M0'8F3(F,(F,(G4.H<3****&$ZAQ,>I[23J3J=5F=I>GFEZ&$P= M/`1SD?I'(UCK(7U1%YZ7?(Q#[MTVHVC6')O8>VSQMP.."BESS\]LR;]-UO2, M)E]K!TT;[U0`X<+A@&PA!&SZ:*5FQDQ>ZX<\%NIY6\5C;=W,USK#36_4E5A4 MRQ/VSA#&V+6$.T',[A2.OW\CFMN==+=`%<6Z;M"Q;&EKK[O"5&+,W`67'Y85 M05D?C97VMGOXIO M:W>KKV;P7TVQ&*DS\//FYK9K96.?TNWKEMU'E7Y:6:B>R9;[R=[H[EY296B. M5YOG-W";MU^+Q."AC/'QMV^CQZX#4[MMN_59ADE;X/X/DF,67/Q+V9&_-?)' M\I:UNR]]5G[8;,>D58RGXO%S1A]\N3JY[;6S/^)>]^WHI+JP5%$HB41:;J!= MOD+:,O=7=_>G=7+?8''Y;B\P\1:??^&KMV\7=[P5D?C97VMGOXIO:W>MYLW@OIMB,5)GX>?-S6S6RL<_I=O7+;J/* MJT^VV#Y`?OT/7\W>JN?/9/?@G^)_IE:WK,#Y_P#N1W_?^[SU3VVP?(#]^AZ_ MF[U4]D]^"?XG^F3UF!\__"Y>&M;Q M6V(N"'%TD4<;+.N^P!=&\:W5XI1ASZ=S:AC?B\LE@"2>&;C0@@-:]SW:6;U# M;%5?"K%*(HSU4U$]C.WF<[W/WUS(V<.>+Q!17SCE\;=OISGI5 M?;R=N_4GAD=;X/X1GF;%ES\.V9DC\U\DGQ+6MV]=+&5;(;,^GE8^GXO"RQE] M\N;HYHM;,SXW6_9T[1`?MM@^0'[]#U_-WJJDO9/?@G^)_IE9'K,#Y_\`N1W_ M`'_N\]4]ML'R`_?H>OYN]5/9/?@G^)_ID]9@?/\`]R._[_W>>JS]L]J2&EIA MI&S=LK0#1ZLDT3E"2;=TDBJJN1(#O..DS*B@0HF.HIO,)0#W@]1+N]GO1'4- M;71T]91&F9(6M$@F;(UKG.:V\F=D(9&`2Y[\SBT#Q3>XUN+;HJBFIGRT]2)G M,!.3(6DAH<;,RND+GFUFML+WZBRM372:I]*(H(U/UWAM.I0D"C$K7!,@@B[= MHI.V[9NV26!40356`'"I5\$(?AF0`!34*??Z!IC>)OGH=EZL43*U^;H#8>R6[RIQJ`U#I1##<@'*7.<1;4`E@R>,, MV?QFEMM"1%WMM@^0'[]#U_-WJJN/9/?@G^)_IE+_`%F!\_\`W([_`+_W>>J> MVV#Y`?OT/7\W>JGLGOP3_$_TR>LP/G_[D=_W_N\]5(D;V@(N4T]N2\VT$MWG M:JS-.4MQ1W@NU^^*T:K)2(-Q*8IR[S?>@,!B&*)0+L4-/,/WWTE9LS68M'2G MCT9C$D!?I::41QN;-P[$$$GW/,',+:)ZU_KZO\!CJAA;W<2F,P#9'N&<5,\1B<]M.0VT%-/5 M9W6&2)[;:9UE>MFSPE\)K6C)-PR2UK3EX,;\X:9@3[;+%!E'PGM-_@JR]=!* MJDHB41*(E$2B)1%03M4?"#$?J:T]/SC)>L/K_AQ+Z)+WS4_U-GV]0NCMT!_L M:;ZP[[*/O'G^RR_M@-(OE<']V3/_`(==!^OAL5\__<5'\E55ZVVT?S7][#_, M3VP&D7RN#^[)G_PZ>OAL5\__`'%1_)3UMMH_FO[V'^8JA:_7A;MZWC'2ML2/ M>3!O;+>/57X+EOM<)O'RIT]CHB)^A%2#D"XZ^.0''+F^W:G"\?QR&IPZ7BQ- MIFL)RO9SB65Q%I&-/1[3>UM?QJZ]W&"5N%89+#5LR/,SG`9FNY>&T7NQY'5I M[]/RCTAKOI>@[23H!J=%CU=7#30NFF<&L:+DGSU M/8`-2=!JH;MN#G-1YZ+U#U$CUHF)AW!)#3735^!,QIQVE1N>Y$@5$AYE5-01 M;MA$Q8PANFYVD(^G5O253*\!EPVL;#E6107DI!PH!&[-`ZQ@]&]542$4.1$BBH)GX M8D-ML#PB7$ZQE.S2^I=8D-:.I-OT#H"X@7%[K4XYB\6&4;ZA^MM`VX!) MI))&;*`4#E'7PQQP8;"!EC`<>W+9N6-M[WOE))S"]BPWU*@F[R M@FDDGQ*8G-(2T=F:[LTCK6`MFL!E-KAXMH%;+70@(Z/70D43"44HU3)A*.[[ M<,!R7:?H'G>C^OTFY6WX>\JO_,?YF%=%;MO?'2_G?L9%K798^#Z8_7)Y_#H^ MHGZ&WWLU'UQ_V%.M]O@^[,7U=OVLRLM70:JA*(E$4-]H#X(KN^B,_C+.JHWX M>\JO_,?YF%3G=M[XZ7\[]C(HN[-MJVO.V-*NYNVX"9=)W8Z;)N92/:.U2I%8 ML3E2*HNFS76O8`?D5@_8[T_^0MG? MW+&__15Y^H+9G_ZNC_\`SP_^"K/U4XS\^J/^-)_Y*M^O^C]N1L`^ONVVJ,*X M8*LDY2+:;$(\[90_)\5JT22PFN*JJ&[:6/-S M('`9[.>7B[+!]KASKEHN&@9=^[-ES.)VP#1KUXBX=VS)J1:"?%,HZ+'F3(NS M,X*HH#S2!SZ20Q@7)>(2UKXR^Y)M M//]*W M/L__``1VG],K_&GM2O3[XZO\`-_8QJ9*M=09>=?:280D? MJ0H$,DS06>0K>0G4F9P_&2RSD5#K)%/A)55`$53!@N[=Q1R8XG'@_?\`4.'T MVU1\$:QKGPL?,&_+N>^YX6&;-Q""7ESNG=UM55S8)[>YQ#7N;'F M^3#18--Q=K79V@ZVMD!LRS?12N\%S$E$7GQJ8,?[8[[;BS[J\I;7[S[QX?*< MIR'PN'NW[_-VYST\.&MX7@WKI?\`RLG`\)HN)Q+>SY\>C?\`VW71 MUMV?X&_@U4.;;+RXA_$)GL^?'HW_`-MTMNS_``-_!IFVR\N(?Q"WBU&]C%;N MW=C(6H#198K9\YM0D?PE%4"[BI+J,`VF,F5;(`8<@!_YU3'9FGV>$UF(.GS`7:)B^X!T):).PEMM.N M7N6V5)EIDHB41*(E$2B)1$HBH)VJ/A!B/U-:>GYQDO6'U_PXE]$E[YJ?ZFS[ M>H71VZ`_V--]8=]E'WCS_9,OM6-/OTQ>7]LCO]/JU_8V[,_.*S]>'_3J$>O# MC/R5/^K)_.3VK&GWZ8O+^V1W^GT]C;LS\XK/UX?].GKPXS\E3_JR?SE6+6FP M8?3FZ6,)".I-TU=6^C*J*2JJ*BH*JNGB!BE,@FW*!=J!1#SWL10 M[+8Q%1T;Y'L?`V0F0M<[,9)&6&2-@M9@[+WOKV*V-A-I:G&Z"2HJ`QKFREG) M<"P8UWPGDWNX_L\EQZ9U^A:Y05([JN=AKAK:.GXM.]],M'S+35SM'<4H+>4O M!NHM$MV"SI18GN305U3)IF(4CDR+HADG*'#4+/H:=^"X-X5?+557*RSM60D! MY\3``")#CU*$L@Q*5!56.BB*(&DY4R(I$,C%,CJ$.X.!UTRF\"I M[MZIB)Y.&TPK!ZO$9A'`PG47/P6WOJYW8-#WFUF@G1:S%<8I,.A,D[P--!\) MUK:-;VG4=PO=Q`U7EB22O+M;ZLH+7#WG&69%'.8S*'PNW@(PX"*;9N=P)$SO M9%1$B9UQ()SFRJ"/`;@BG<4_@>RN%GAV=._IFZR/\I`UR,!OEN`.F;._,:<@ M\,VJQ0<2[8&=\JO\` MS'^9A4^W;>^.E_._8R+3^RQ\'TQ^N3S^'1]1/T-OO9J/KC_L*=;[?!]V8OJ[ M?M9E9:N@U5"41*(H;[0'P17=]$9_&6=51OP]Y5?^8_S,*G.[;WQTOYW[&1:; MV6/@^F/UR>?PZ/J)^AM][-1]X@F^1H9E)`=9[XP?&NK'W6X?--CC)FCDA:\N.MN M9CF-%^F8EUP"1RM<1XJU3LK0#AE;ER7$L*Q$YZ308M$543$*9*+*KETDL8V% M2G5='1\TN"F1,&1')21GT->"208565[[@5$C6-!;8%L`=[8UWPPYTKF:"S71 M.%R;ANZWPXDR6NIZ9MB8F.<3>]C(?%(^"0UC7>4AXT`LK4UTFJ>5:.U1\'T/ M^N+7^&2/K"N??1)>]FG^N1_8U"M7=!]V9?J[_P#OB[QY_I5=K/T"O&]K=C[F MBI.VF["3Y@$$G[A\1W)IU)I1MP(HB5TCQV$DQ,HHR=E`/=0054!(V]$Q@*H4Q"F#H; M&PQ###ML]A<5V7JVT][-9X.CK6)&5S#J`+WOXHM;6^@^U8T^_ M3%Y?VR._T^H1[&W9GYQ6?KP_Z=27UX<9^2I_U9/YR>U8T^_3%Y?VR._T^GL; M=F?G%9^O#_IT]>'&?DJ?]63^.3AL([6#`"`#NZ@."[:S]#573MQRKI@[VI]-G<+#5\N=THB41*(E$2B)1$ MHBJ'K]I??5ZWC'2ML08R;!"V6\>JOSK!OAP1X]5,GL=.43]"*D'(%QU\<@.. M7-]N[G:''\+$VF:PGB1,YQ+,XBTCVGHX&]K:_C5U;N-KL*PO#)(:N M;(\S.[E,;!>[`1U![_\`J+>5U&J52B*H>OVE]]7K>,=*VQ!C)L$+9;QZ MJ_.L&^'!'CU4R>QTY1/T(J0<@7'7QR`XY)$S MG$LSB+2/:>C@;VMK^-75NXVNPK"\,DAJYLCS,YP&5[N4QL%[L!'4'O\`^HL? M?T\\M6Q+UN>/3;+/[\;;EQRUMOG)6BUXNHI)BHO@$%56?.D!L*@F#8JJ+LO"R&#"`DSO$I3V[O(P MNHJ*>*>-N9L.?/Y0'9>:W:!EYO)UZ`D5%NXQ2GIZB6"1V5TV3)Y"6YN6_E.; ME\O3K8'V`A%"'C&>#@(BD)L9\[QSU`1,/YP>D?'QJE%=:_27F8BWX]Q+STK& MPD2TVH&1M+W'H&@DG MMZ#7HO*>HBA87R.#&CJ7$`#LZG3JJ*:H=N>WHL%HW2F(&YGN``+FGTG#2*)G M@*?8\>/!?.LE,ND;BBUX:A2G+QTQZV5@^[:>3GK7\,?$;8O[>KM6-[#IGN-# ME*K7&-Y$$?)1,XA^.ZX9V=&Z/=VC7)8Z\P52(.TM4^T?TG_T M+``*<4R%3+PR$V$)YI0^/TY__:URV*CC6"WY>Z=.;B@H%ISTJ^!CRK7BHH[^ M#)-G"GNK@Z:9<)IF'JI@=;C&R]7144?$GDX65MVMOEGB>[5Y:T6 M:TG4_M4KV(Q*GP_&H*BH=DC;GN;$VO$]HT;<]2!HJN6M:':6LJ/6BK8CN[6" M[P\@JAQ[6<;ESID2,?>[65.&2))A@!QT\.HUSCLULKO7P"F=38=#PHG/SD9J M)_.6M:3>1SCT:!:]M.E^MNXSCNPV*3":K?Q'AN4'+4MY07$#ERCJ?V_HV;[K MGZ^1GK]?T?7PD/\`?7Y^EZU-]W/GX7W]_P"+SZ;EI_[8ORNB?+O\E/LKO7\F M?Y&ORWXO'F?PCA>\_;YN:E>P_KH>G=/Z=?X#GXG^#^2?D]Q]L]TR^+^7ENM' MM+ZBO2Z7TN_Q/+D_Q'QQF]T.3Q+]?R:]++5T&JI4::P6_+W3IS<4%`M.>E7P M,>5:\5%'?P9)LX4]U<'33+A-,P]3AX8#K5?;U,#K<8V7JZ*BCXD\G"RMNUM\ ML\3W:O+6BS6DZG]JE>Q&)4^'XU!45#LD;<]S8FUXGM&C;GJ0-%5RUK0[2UE1 MZT5;$=W:P7>'D%4./:SC%$Y^C0+7MITOUMW&<=V&Q2835;^(\-R@Y:EO*"X@? M&IS$&@-XDTOA4N7F(;&ULCM`[Q@^2,#.7-SG,%N:K>1L]AD&7#8@\N).6-A@ M9?07<2T:EO0M8[Q0#ETM=NWH*/MB$BX"*3X;")9ILT,E3*<^P//76X1$R&56 M/E10P%#<FNOL"P6FPC#X*&F%HH6!HZ`FW5SLH:"]YN][@!F>2[M5!XGB M,U?5RU,QN^1Q<>MAY&BY)RM'*T7-F@#L69K;+`4':_6?<=ZV=&Q5L1W>;]O< MJ$@LAQVS?"!&+U$Q][I5$@X.J0,`;/7P\1"G=]NRN*8_@<--AT/%E;4L>1F8 MSD$4S2;R.:.KFZ7OKTZJP-W&.46%XE)-5R9&&%S0;.=S%S"!9@)Z`]RV;1^W MY>UM.K>@IYIR,JQ%_P`TUXJ*VSC2;IPE[HW.HF.4U"CT,/C@<#TJ0[J\#K<' MV7HZ*MCX<\?%S-NUULT\CQJPN:;M<#H3WZK5;;XE3XAC=144[L\3\EC8B]HV M-.CK'J#V+9;MM*#O:#=0$^UYAFX\]-5,0*X:KE`02=-%1`>&JGD<#@0$!$AP M,0QBC(-J-E\/V@P]]%6LS1NU!&CXWCQ9(W:Y7MOIH002UP.OQ7-[6N':T_I!LYI#@"*8Q>D6M6G5WGE+,9)2J;%84F\BF\8(-9-D M?SQ;NV3IXDJ!3AM!0@^].7UIL M]H!6.[1GC):X=K7"Q+;9FM==HY^KH8HIWLAE$ ML8/*\!SW7"QWD8=)O;;< MS5)4YQ*P5+(@54QFX8+OW&`Y=IA,!A,0G.^U]+O5AQ6;TJJ!-1N)='9M&PQM M<3[4X3-#B8^F:[@]N5Q(<7,;;.`3[$24,?AT1CJ`+.UJ'9B!XXX;K6=URV;E M-Q;+9RU3[KGZ^1GK]?T?7PC/]]?GZ7KE]W/GX7W]_P"+SZ9_0#22Z[*F)>Y+I21BU%XT\(SB0509"Z M-SFM`R!K6W+G$N)RAK>)KMY.VN'XI314M(3(`_B%]G-`L'M#0'`$DYKDV`&E MKW(9:FNDU3R41*(E$2B)1$HB41*(E$2B)1%K%ZV_Y66===K"Z.Q\I;VE[7\J\![HM.Y++EW$#=4*_@Y5N)MS5^F).(F"AT M@7;*AE-PB4=FE['M!L1<&Q':%S#6 MT%11RF.=A8[R'\9%QV$7!LX7!["LRPU1U,BFK9C&:B7U',62)&[-FPGI5N@@ MDD3AI)(I)."D3*0GF@!0``#H%8\F"8<]Q^H,HK**A/W5*/E00'$ M-Q$2D(4%%,XV%#\T*\:G$L,PJ/(]\<+0+A@L#8GJV-NIN;]&^4GM7M38;B>* MR9V,DF<38O-R+@='2.T!`MU=Y`.Q6OTT[*02)VCN[G"K[CCYL?'@X2:8W&2- MO1/)R43.&/CNL7]G1NK&]HUSW&HRE67@^[ M>"/GK7\0_$;<,[>KM'N[#IDL=.8+T7M6P8^#:(I$3*FDW32;LTF&$$TT4@V) ME22+A,B9"=`*4,8Z%R&!-6]/^*=V\MW;R7]"=\7B\W_`#=NWTYZ2W9;9;TXXWMO M#X>7X.:^;-])MK95$MJ=J?2?A>U<3B9OA9;9U88[%!W+Z;3<4 ML\T1S%FXY2'$6K1\@U(["27*5NF14FX!*)3GSI-B>$+N)![P,&/;7D!?3.:33.G`YG='N:T&T?*UP M;FXILT`CN)ZSCMB6NPO+3^UY&`Y5E=MMVW,7#.&DRIIVV[N1B1^@T<%>-&R+ ME!LBY:JK.BN"%*DH8VS>D*0_;=@JA]+43-DN8GR-:W+[J(G9219Q()(<&LRG M4#6QNOAVWM.RJIX71V$C(W.=F]R,K2'EI]M>_LAAJ?"/=>#ID MZ<9S&]<^N7/?H+V[%Y.V]M734W@_N7&US]>"U[NF33-DMU-K]J[-F]L^TKKE M;4B5[=O1X9VLY;VXA!,Y"1(1+8Q*M*'79L..<$DR`F"I"E%90%" M$^<0W?5--'*\2!V5T;8Q:QD,A8WXUF`.=87)O8DY18G[P_>!35,D3#&6YFR. MD-[B,1A[OBW>2UES8"UP!F-P-;9]NRW%[+FI]S9#EM\F`TCY3`1(US0&9QS!USFS6!LW*;\AL2S7FY=DD^U5=L:10(XXY3#P^)PQ2,)1$=6-FX)&,DAJ<\;ZED`/#+?'8'%]BZ M_*26Y>VU[ZK9G:2>-[XYJ;)(RF?.1Q`[Q'EH9<-MS`!V;LO:VBC?VU.H7_0/ M_EO[+GY;QOY)_I7\7_\`L?A'_I5M_450_/\`_;<#W%WNWQ/'_P";Q>]:GU:U MWS#_`&/']V;[C\?Q/^7QNY9*2[5,T""SRWM*.^(V&MNR9B[I23NR+A&D2[OE MHW=130%7K<>.@7FDTSNC`D4A@.94B2104-XQ;%17#9:O*YSYFL`B<\O%.2'G ME.AY20S6^EB2;#UEVUEL714F9K60N>3*U@89P"P)WQ4T5YMLD''CEF+Q!L9+[+(NR2.FLJ*RQ4@3(8JP M&+B2[&5#,';7YKFP<8[:AAZ.#@3?EL\@@96WN;MLH/LIZ>V_?G='<7?O/?:KFN=X')23F/_">"WW[ M^7W_`'H,9QUQD=%CN%^EU=)39\^2VMLM[M#NESY;=5O,"Q3TQH8ZG)DSWTOF MME<6];#R7Z*2*U*VR41*(E$2B)1$HB41*(E$2B)1$HBU*Z;,M>\F?=]S6Y%3 MS8JX.$22[5!VFFL!`2!=,BH^:K M*B5C',:XAK[9@";.MJ,PZ&QZ7Z+R?3Q/>U[F@N9?*2!=M]#E/47'6W5=9Y;5 MN2+QU(2%OPCY^^A%+:?/GC%JLX<1"QQ46BEUE""=1HH<1,9`PBF(CD2YK[CJ MYV-#6R.#0[.`"0`\='@=COI=5\24D#W%SHVEQ;D)(!)8>K">UOT>BPC;333E ME'R<0SL"R6D3-\OWS&-H.,2:/^34%9ISK MU[JB4N9?*2]UVWT.4WN+CK;JL9F$4+&.8VGB#7VS`,;9UM1F%K&QZ7Z+K/-* M-+9%XZD)#36P'S]\Y4>/GSRWHE9PX<+'%19==91N)U#J'$3&,81$1'(]:^H\ M;Q%C0UM3*&@6`$C@`!T`%]`OF3!,.>XN=31%Q-R3&TDD]23;4HZTHTM?*E7? M::V`\6(V;LR+.K>B53E;M&Y&C1`#*-Q$"(()$23+X$(4I2X*`!1F-XBP6;4R M@7)TD<-2;D]>I))/E.J/P3#GF[J:(FP&L;3H!8#IT```\@T62=6#8CY(J#ZR MK2>(DA&]M$1=1$>J0L0T<$=M(H"J(B`-$%TB*IH?>R'*4Q2@8`&O)F)UC#=L MT@.8OT>XPO?H+FWDN?*O(X)AV4-\&BR@DVX;;7-KFUNIL+^6P\B M+Z4:6NDF:#G36P'",LCP"E^29XG#\4>Y_)]/$^CT[EC9'333F8Y#O>P+)E>ZHU&&C.\8.,<\FP; M;N78M>,@;@H([C;$R8(7(X`,U[18O719LE1*W,2XV>X7<>KC8ZD]IZKQEPBA MERYZ>)V4!HNQILT=&BXT`[!T799V#8DBW;RZ) M`31E4$4T0(F[3(`%*N4`4``P!L5\28G6/<7.FD+BW(27N)+#U83?5OT>B^X\ M,HV-#6PQAH=G`#&@!XZ/`MH[Z75(&P;$M5XI(6Q95I6X_6;&9JOH&(CX]P=N M8Y%#('6:(IG$@G3(82B.,E`?$`I4XG65#G@&?BZ?M].OT_P".:(ONB)1$HB41*(E$2B)1 M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B C)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB_]D_ ` end -----END PRIVACY-ENHANCED MESSAGE-----